Advertisement
New Zealand markets close in 1 hour 28 minutes
  • NZX 50

    12,418.08
    +108.17 (+0.88%)
     
  • NZD/USD

    0.5974
    -0.0007 (-0.12%)
     
  • NZD/EUR

    0.5480
    -0.0008 (-0.15%)
     
  • ALL ORDS

    8,224.00
    +57.60 (+0.71%)
     
  • ASX 200

    7,987.60
    +55.90 (+0.70%)
     
  • OIL

    79.95
    +0.17 (+0.21%)
     
  • GOLD

    2,398.30
    +3.60 (+0.15%)
     
  • NASDAQ

    19,822.87
    +300.25 (+1.54%)
     
  • FTSE

    8,198.78
    +43.06 (+0.53%)
     
  • Dow Jones

    40,415.44
    +127.91 (+0.32%)
     
  • DAX

    18,407.07
    +235.14 (+1.29%)
     
  • Hang Seng

    17,599.30
    -36.58 (-0.21%)
     
  • NIKKEI 225

    39,676.34
    +77.34 (+0.20%)
     
  • NZD/JPY

    93.4110
    -0.4050 (-0.43%)
     

BioLife (BLFS) Progresses in Cell & Gene Therapy With CryoCase

BioLife Solutions, Inc. BLFS, a key player in bioproduction tools and services for cell and gene therapy (CGT) and the broader biopharma market, has unveiled its latest innovation, CryoCase, at the International Society for Cell & Gene Therapies (ISCT) event in Vancouver, Canada.

This latest addition to the company’s CellSeal product line is set to be released to CGT developers in August and is currently available for demonstration.

More on CryoCase

CryoCase is the first cryo-compatible rigid container designed for closed-system fill and retrieval of larger volumes of fluid, up to 75mL. Its transparent design enables improved compliance with USP 790, USP 1790 and other international visible inspection methods.

ADVERTISEMENT

Manufactured under stringent environmental and processing controls, CryoCase addresses the common issue of particulates in single-use disposable manufacturing. Early tests indicate that CryoCase offers comparable cell viability and recovery rates to existing storage bags and boasts a high resistance to leaks or fractures when subjected to frozen state drop testing.

Integration and Compatibility

Designed with volume versatility and a rigid, protective structure, CryoCase integrates seamlessly with existing systems, enhancing throughput and streamlining procedures. This innovation is compatible with various downstream processing systems, including BioLife's own Signata CT-5. This compatibility underscores CryoCase’s potential to reduce overall risks and costs in CGT manufacturing and distribution.

Zacks Investment Research
Zacks Investment Research


Image Source: Zacks Investment Research

Addressing Industry Challenges

The introduction of the CryoCase comes at a crucial time when particulates in reagent manufacturing and final drug products are increasingly problematic. By offering a better primary container and a true closed-system approach, BioLife Solutions aims to mitigate these risks, ultimately facilitating safer and more efficient production of life-saving therapies.

Market Prospect

According to a BCC Research report, the global market for cell and gene therapy tools and reagents is estimated to reach $13.7 billion in 2027 from $8.3 billion in 2022, at a CAGR of 10.6%.

Share Price Performance

Year to date, shares of BLHS have surged 33.9% compared with the industry’s 2% growth.

Zacks Rank and Key Picks

BioLife carries a Zacks Rank #4 (Sell) currently.

Some better-ranked stocks in the broader medical space are Hims & Hers Health HIMS, Medpace MEDP and ResMed RMD. While Hims & Hers Health and Medpace sport a Zacks Rank #1 (Strong Buy) each, ResMed carries a Zacks Rank #2 (Buy) at present.  You can see the complete list of today’s Zacks Rank #1 stocks here.

Hims & Hers Heath stock has surged 127.9% in the past year. Estimates for the company’s earnings have risen from 11 cents to 18 cents for 2024 and from 25 cents to 33 cents for 2025 in the past 30 days.

HIMS’ earnings beat estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 79.2%. In the last reported quarter, it posted an earnings surprise of a staggering 150%.

Estimates for Medpace’s 2024 earnings per share have moved up to $11.29 from $11.23 in the past 30 days. Shares of the company have surged 86.3% in the past year compared with the industry’s 4.5% growth.

MEDP’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 12.8%. In the last reported quarter, it delivered an earnings surprise of 30.6%.

Estimates for ResMed’s fiscal 2024 earnings per share have moved to $7.64 from $7.59 in the past 30 days. Shares of the company have decreased 0.7% in the past year against the industry’s rise of 2.9%.

RMD’s earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 2.8%. In the last reported quarter, it delivered an earnings surprise of 10.9%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

ResMed Inc. (RMD) : Free Stock Analysis Report

BioLife Solutions, Inc. (BLFS) : Free Stock Analysis Report

Medpace Holdings, Inc. (MEDP) : Free Stock Analysis Report

Hims & Hers Health, Inc. (HIMS) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research